- UPSpace Home
- →
- Health Sciences
- →
- Surgery
- →
- Research Articles (Surgery)
- →
- View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
| dc.contributor.author | Dlamini, Zodwa
|
|
| dc.contributor.author | Hull, Rodney
|
|
| dc.contributor.author | Mbatha, Sikhumbuzo Z.
|
|
| dc.contributor.author | Alaouna, Mohammed
|
|
| dc.contributor.author | Qiao, You-Lin
|
|
| dc.contributor.author | Yu, Herbert
|
|
| dc.contributor.author | Chatziioannou, Aristotelis
|
|
| dc.date.accessioned | 2021-09-10T13:17:28Z | |
| dc.date.available | 2021-09-10T13:17:28Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Alternative splicing (AS) is a method of increasing the number of proteins that the genome is capable of coding for, by altering the pre-mRNA during its maturation. This process provides the ability of a broad range of proteins to arise from a single gene. AS events are known to occur in up to 94% of human genes. Cumulative data have shown that aberrant AS functionality is a major factor in human diseases. This review focuses on the contribution made by aberrant AS functionality in the development and progression of esophageal cancer. The changes in the pattern of expression of alternately spliced isoforms in esophageal cancer can be used as diagnostic or prognostic biomarkers. Additionally, these can be used as targets for the development of new treatments for esophageal cancer. | en_ZA |
| dc.description.department | Surgery | en_ZA |
| dc.description.librarian | pm2021 | en_ZA |
| dc.description.uri | http://www.dovepress.com/cancer-management-and-research-journal | en_ZA |
| dc.identifier.citation | Dlamini, Z., Hull, R., Mbatha, S.Z., Alaouna, M., Qiao, Y.L., Yu, H., Chatziioannou, A. Prognostic Alternative Splicing Signatures in Esophageal Carcinoma. Cancer Management and Research 2021;13:4509-4527. https://doi.org/10.2147/CMAR.S305464. | en_ZA |
| dc.identifier.issn | 1179-1322 (print) | |
| dc.identifier.other | 10.2147/CMAR.S305464 | |
| dc.identifier.uri | http://hdl.handle.net/2263/81754 | |
| dc.language.iso | en | en_ZA |
| dc.publisher | Dove Medical Press | en_ZA |
| dc.rights | © 2021 Dlamini et al. This work is published and licensed by Dove Medical Press Limited and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. | en_ZA |
| dc.subject | Esophageal squamous cell carcinoma | en_ZA |
| dc.subject | Adenocarcinoma | en_ZA |
| dc.subject | Splice variants | en_ZA |
| dc.subject | Cell surface receptors | en_ZA |
| dc.subject | Therapeutic targets | en_ZA |
| dc.subject | Biomarkers | en_ZA |
| dc.subject | Alternative splicing | en_ZA |
| dc.title | Prognostic alternative splicing signatures in esophageal carcinoma | en_ZA |
| dc.type | Article | en_ZA |
